The purpose of this study was to evaluate a possible association between mammary tumour size and increasing degree of malignancy. Data of 625 dogs with a total of 1459 mammary tumours were analysed retrospectively. 80.3% dogs were intact, mean age at diagnosis was 9.7 ± 2.5 years, 75.8% were pure breed dogs. Median body weight was 20.0 kg. Malignant tumours (n = 580) were significantly larger than their benign counterparts (1.94 cm vs 0.90 cm in mean, respectively; P ≤ .0001), resulting in a positive correlation between increasing tumour size and a change from benign to malignant (P ≤ .0001; r s = 0.214). When malignant tumours were grouped into four degrees of increasing malignancy (complex/simple/solid/anaplastic carcinomas) a significant positive correlation between increasing tumour size and more malignant tumour degree (P ≤ .0001; r s = 0.195) could be demonstrated. In a number of cases, highly malignant tumours were found to arise within less malignant lesions, supporting the concept of a further progression within the malignant tumour subtypes. In patients with multiple tumours, mean tumour sizes for malignant tumours were significantly smaller compared to patients with only one tumour (1.67 vs 2.71 cm in mean, respectively; P < .0001). These findings suggest that mammary tumours progress not only from benign to malignant but also from low to highly malignant. An increase in diameter of only a few millimetres may therefore have a big impact on the patient's outcome.
Localized histiocytic sarcoma may occur as a primary lesion in periarticular tissues of large appendicular joints. Treatment options for the primary lesion include radical surgical excision, radiation therapy (RT), or both, in combination with chemotherapy for potential systemic metastases. In an effort to better characterize the time to progression (TTP) following surgical vs non-surgical approaches for periarticular histiocytic sarcoma (PAHS), a contemporary European population of affected dogs was retrospectively surveyed. Medical records were queried for newly-diagnosed PAHS cases undergoing surgery (predominantly limb amputation) or RT followed by systemic chemotherapy. Of 49 dogs, 34 underwent RT and 15 underwent surgery. All dogs received adjuvant chemotherapy. There was no statistically significant difference in TTP or overall survival between groups. The median TTP was 336 days for the operated dogs and 217 days for the irradiated dogs (P = .117). The median overall survival time was 398 days for the operated dogs and 240 days for the irradiated dogs (P = .142). On multi-variable analysis, the variables significantly associated with an increased risk of both tumour progression and tumour-related death were regional lymph node and distant metastasis at admission. Survival and local control rates following RT may be comparable to radical resection. These data may better inform shared decision-making processes between multidisciplinary care providers and owners.
Influence of neutering on canine mammary tumorigenesis has been a source of vivid discussion over the last decades. The purpose of this retrospective study was to describe the association between neuter status, tumour size and degree of malignancy in a large population of 625 female dogs with altogether 1459 removed mammary tumours (MTs). MT‐bearing dogs were predominantly intact (80.3%) and intact dogs were overrepresented in the tumour population compared to the control group of >19 000 females (p < .0001). Multiple MT occurred in 340 patients (54.4%) and were significantly more common in intact dogs (57.8% vs. 40.7% spayed). Neutered dogs were not only significantly more likely to have a malignant MT (p < .0001) but were significantly more often affected by more aggressive tumour subtypes (p < .0001). Positive correlation between increasing tumour size and increasingly malignant phenotype was slightly stronger in spayed (rs = .217; p = .021) compared to intact (rs = .179; p = .0003) patients. After ovariectomy, progression from benign to malignant occurs in smaller size tumours, as MT ≥2 cm in diameter were malignant in 86.9% of the spayed patients, compared to 62.0% in intact patients (p = .0002). Intact bitches have a higher risk for MTs and tumour multiplicity. MTs in neutered females are more often malignant and belong to more aggressive subtypes compared to MTs in intact dogs. In neutered bitches, histologic progression from benign to malignant and further along the cancer progression continuum occurs at smaller tumour sizes.
Urothelial carcinoma (UC) is the most common tumour of the canine urinary bladder. Recently, BRAF mutation testing emerged as a diagnostic option, but its prognostic significance is unknown. This study investigates the relationship between BRAF (variant V595E) mutation status and overall survival in UC‐bearing dogs. Seventy‐nine patients histologically diagnosed with UC of the bladder and/or urethra between 2006 and 2019 were included in this retrospective single‐centre‐study. Treatment consisted of meloxicam (n = 39, group 1 ‘Melox’), mitoxantrone and meloxicam (+/− followed by metronomic chlorambucil; n = 23, group 2 ‘Chemo’) or partial cystectomy followed by meloxicam +/− mitoxantrone (n = 17, group 3 ‘Sx’). Survival was significantly influenced by treatment (p = .0002) and tumour location (p < .001) in both uni‐ and multivariable analyses. BRAF mutation was identified in 51 tumours (=64.6%) and had no statistically significant influence on overall survival: MST for BRAF‐negative patients 359 versus 214 days for BRAF‐positive dogs (p = .055). However, in BRAF‐positive dogs, survival depended significantly on type of treatment in univariable analysis: MSTs for groups 1–3 were 151, 244 and 853 days, respectively (p = .006); In BRAF‐positive group 2 (‘Chemo’)‐patients, adjuvant metronomic chlorambucil after mitoxantrone more than doubled MST compared to patients receiving mitoxantrone alone (588 vs. 216 days; p = .030). In contrast, MSTs were not significantly different in BRAF‐negative patients among the three treatment groups (p = .069). Multivariate analysis of these data was not possible due to group size limitations. This study identified tumour location and treatment type, but not BRAF mutation status, as independent prognostic factors for overall survival.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.